11:57 AM EDT, 06/25/2024 (MT Newswires) -- Quince Therapeutics ( QNCX ) said Tuesday it has dosed the first patient in its phase 3 trial to evaluate the neurological effects of EryDex in patients with Ataxia-Telangiectasia.

The study plans to enroll about 86 patients aged six to nine and about 20 aged 10 or older, the company said, adding that it expects to announce topline results in the second half of 2025 with a potential new drug application submission in 2026.

With the achievement of the first patient enrolled in the study, Quince said it will make a $5 million cash milestone payment to former EryDel shareholders. Quince acquired EryDel in October 2023.

Ataxia Telangiectasia is a rare, inherited genetic disorder that affects the nervous system and immune system.

Price: 0.69, Change: -0.01, Percent Change: -1.56